-
Posted by
Two Blokes Apr 23 -
Filed in
Stock
-
4 views
MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announce review of their January 2016 Research Collaboration and License Agreement (the “2016 Agreement”) with Sanofi: As previously disclosed and in alignment with its current strategic priorities, Sanofi will opt to pursue the development of SAR'514/IPH6401 (BCMA ANKET\u00ae) in autoimmune indications under the terms of the 2016 License Agreement; In alignment.
